News | March 01, 2025
Biocon launches GLP -1, Liraglutide, in UK
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Subscribe To Our Newsletter & Stay Updated
